Popular Articles
Burdock Root

Patient Enrollment Complete For Phase I/II Clinical Trial For GALNS For Morquio A Syndrome
BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) announced that patient enrollment has been completed for the Phase I/II clinical trial for BMN-110 or N-acetylgalactosamine 6-sulfatase (GALNS), intended for the treatment of the lysosomal storage disorder Mucopolysaccharidosis Type IVA (MPS IVA), or Morquio A Syndrome. The company expects to report initial results in the first half of 2010.
generic viagra online
Liver Transplantation After Drug Induced Acute Liver Failure Examined By Study
Liver transplantation offers a good chance for survival for patients with drug induced acute liver failure, however, certain pre-transplant factors are associated with worse outcomes. Patients who are on life support, who have elevated serum creatinine, and children whose liver failure was caused by antiepileptic drugs did not fare as well after transplantation. These findings are in the July issue of Liver Transplantation, a journal published by John Wiley & Sons. The article is also available online at Wiley Interscience.
News of the day
Evidence For A New Genetic Link To Therapeutic Efficacy For Alzheimer's Disease
Accera, Inc., a biotechnology company delivering breakthrough therapies in central nervous system diseases, today announced further evidence for genetic interactions impacting the efficacy of the ketogenic compound AC-1202 (Axona(TM)) in Alzheimer"s disease. New data from the company"s previously completed double-blind, placebo-controlled trial in patients with mild-to-moderate Alzheimer"s disease demonstrates an interaction between two genetic markers that strongly influence the therapeutic response in patients. Dr. Samuel Henderson, Executive Director of Research, will present these results at the 2009 International Conference on Alzheimer"s Disease (ICAD) sponsored by the Alzheimer"s Association.
Medical Devices

State Senior And Disabilities Services Responds To Federal Review

The state Division of Senior and Disabilities Services is working this summer in coordination with the Centers for Medicare & Medicaid Services (CMS) to improve its compliance with federal standards in the areas of Home and Community Based Medicaid Waivers and Personal Care Services (Personal Care Assistance). "We greatly appreciate the thorough and helpful review that CMS recently completed and we are eager to work hand-in-hand with them in any way that will better serve Alaskans who use and need our services," said Rebecca Hilgendorf, Director of Senior and Disabilities Services. The CMS review cited several areas in need of improvement to assure that the state"s oversight of the Waivers and Personal Care Services is consistent with federal and state regulations. While the improvements are ongoing, the state cannot accept new applications for the Home and Community Based Services Waivers or Personal Care Services at the direction of CMS. The department is evaluating other programs available to provide interim services to the persons who are affected by the CMS-imposed moratorium. "This is only a temporary moratorium while we catch up with a backlog of assessments and implement systems designed to ensure the health, safety and welfare of Alaskans," Hilgendorf explained. The division will also assure that its staff and managers responsible for the Home and Community Based Services and Personal Care Services programs attend Web-based waiver training, which is sponsored by CMS. Following the training sessions, the division will develop a work plan and timeline to implement a quality-improvement strategy and end the moratorium. "After our plan is developed, we will submit it to CMS for approval," Hilgendorf said. "Our goal is to quickly resolve the areas of concern while strengthening Alaska"s long-term care system for now and the future." DHSS is now on Twitter. Follow health updates at http://www.twitter.com/Alaska_DHSS. Centers for Medicare & Medicaid Services


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):